Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Review Worldwide Dividend ETF Performance 5 Year to gauge long-term resilience, consistency, and income potential.
24,171 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A popular SPIA offers $2,200 monthly from a $350,000 lump sum, yet the contract hides key costs: fixed payments, loss...
Small-cap stocks are delivering the sharpest outperformance versus the S&P 500 in years, with a roughly 20% YTD g...
Alphabet's Gemini delays raise questions about AI leadership and stock resilience. This guide analyzes what the lag m...
A dramatic drop can set the stage for a smart rebound. This guide explains how to analyze a growth stock down right, ...
When a CEO unloads a big chunk of stock, investors take note. This article digs into sentinelone's sold over 39,000 s...
Meta Platforms is negotiating a landmark AI hardware pact with AMD that could top $100 billion, including an option f...
Nvidia unveils a $2 billion investment in Lumentum, pairing strategic scale with a fast-growing demand for AI-grade o...
Regulatory uncertainty over RESPA is transforming agent referrals into a legal battleground, pushing lenders and brok...
Tech-led selling pushed the Nasdaq Composite lower as investors weigh higher yields and fresh data. The broader marke...
Berkshire Hathaway just repurchased stock, signaling a shift in how the company’s massive cash pile may be deployed. ...
Meghan Markle headlines a luxury weekend in Sydney, priced like a premium wellness retreat. This deep dive explains w...